Muscular Dystrophy Program

About Pliant Therapeutics

Pliant Therapeutics is pioneering a new approach to treating fibrotic diseases by targeting the biological pathways that drive fibrosis, specifically through integrin-mediated activation of TGF-β. The company's most advanced program, bexotegrast, has demonstrated promising safety and efficacy signals in mid-stage clinical trials for IPF and PSC, positioning it as a potential first-in-class oral therapy. With a robust pipeline of integrin-targeted candidates and a strong intellectual property position, Pliant aims to address the substantial market opportunity in fibrotic diseases, which currently lack effective anti-fibrotic treatments.

Therapeutic Areas